NOTVQ (Inotiv) Total Receivables: $74.7 Mil (As of Mar. 2026)


What is Inotiv Total Receivables?

Inotiv NOTVQ -9.91% Total Receivables is $74.7 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Inotiv's Total Receivables for the quarter that ended in Mar. 2026 was $74.7 Mil.

Inotiv Total Receivables Historical Data

* Premium members only.

The historical data trend for Inotiv's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv Total Receivables Chart

Inotiv Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.36 100.44 90.42 77.44 97.45

Inotiv Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.35 91.85 97.45 88.54 74.70

Inotiv Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $74.7 Mil mean?
Inotiv (NOTVQ) has a Total Receivables of $74.7 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Inotiv and its competitors.
Is Inotiv's Total Receivables too high?
Inotiv's current Total Receivables is $74.7 Mil.
How does Inotiv's Total Receivables compare to NDRA and XWEL?
Inotiv's Total Receivables of $74.7 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Diagnostics & Research company?
A good Total Receivables depends on the Medical Diagnostics & Research industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Inotiv and its competitors. Inotiv's current Total Receivables is $74.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current Total Receivables is $74.7 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Total Receivables is $74.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges BS50:Germany
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.